| Literature DB >> 31867552 |
Syed Raza Shah1,2, Zarbad Shah2, Ajmal Khan1, Ayaz Ahmed3, Javid Hussain1, Rene Csuk4, Muhammad U Anwar1, Ahmed Al-Harrasi1.
Abstract
Diclofenac or 2-[(2',6'-dichlorophenyl)amino]phenyl}acetic acid (dcf) is a nonsteroidal anti-inflammatory drug, and 1,10-phenanthroline (phen) is a well-known enzyme inhibitor. In this study, three new alkali metal complexes (1-3) containing both phen and dcf were prepared, and their structures were characterized by a variety of analytical techniques including infrared and UV-vis spectroscopy, 1H NMR and 13C NMR elemental analysis, mass spectrometry, and single-crystal X-ray diffraction analysis. In these complexes, phen binds via a N,N'-chelate pocket, while the monoanionic dcf-ligand remains either uncoordinated (in the case of 1 and 3) or coordinated in a bidentate fashion (in the case of 2). All three complexes crystallize in the triclinic space group P-1. [Na2(phen)2 (H2O)4][dcf]2 (1) is a dinuclear sodium complex, where two crystallographically identical Na+ cations adopt a distorted five-coordinate spherical square-pyramidal geometry, with a [N2O3] donor set. [K2(phen)2(dcf)2(H2O)4] (2) is also a dinuclear complex where the crystallographically unique K+ cation adopts a distorted seven-coordinate geometry comprising a [N2O5] donor set. [Li(phen)(H2O)2][dcf] (3) is a mononuclear lithium complex where the Li+ cation adopts a four-coordinate distorted tetrahedral geometry comprising a [N2O2] donor set. The complexes were evaluated for their anticancer activity against lung and oral cancer cell lines as well as for their antibacterial potential. The prepared complexes displayed very good antibacterial and anticancer activities with an excellent bioavailability.Entities:
Year: 2019 PMID: 31867552 PMCID: PMC6921677 DOI: 10.1021/acsomega.9b03314
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1Synthetic routes to [Na2(phen)2(H2O)4][dcf]2 (1), [K2(phen)2(dcf)2(H2O)4] (2), and [Li(phen)(H2O)2][dcf] (3).
Figure 2Molecular structure of [Na2(phen)2(H2O)4][dcf]2 (1); thermal ellipsoids are drawn at the 50% probability level.
Selected Geometric Parameters (Å, deg) for 1a
| Na1–O2 | 2.334 (2) | Na1–N2 | 2.433 (2) |
| Na1–O1i | 2.406 (2) | Na1–N1 | 2.491 (2) |
| Na1–O1 | 2.411 (2) | Na1–Na1i | 3.208 (2) |
| O2–Na1–O1i | 82.63 (8) | O2–Na1–N1 | 157.10 (10) |
| O2–Na1–O1 | 85.75 (8) | O1i–Na1–N1 | 115.12 (7) |
| O1i–Na1–O1 | 96.51 (7) | O1–Na1–N1 | 105.32 (7) |
| O2–Na1–N2 | 92.98 (10) | N2–Na1–N1 | 67.55 (7) |
| O1i–Na1–N2 | 112.01 (8) | Na1i–O1–Na1 | 83.49 (7) |
| O1–Na1–N2 | 151.08 (8) |
Symmetry code: (i) −x + 1, −y + 1, −z + 1.
Figure 3Molecular structure of [K2(phen)2(dcf)2 (H2O)4] (2); thermal ellipsoids are drawn at the 50% probability level.
Selected Geometric Parameters (Å, deg) for 2a
| K1–O1 | 2.742 (3) | ||
| K1–N1 | 2.767 (3) | K1–O1ii | 3.100 (3) |
| K1–N2 | 2.782 (3) | K1–O3ii | 3.187 (3) |
| K1–O4i | 2.873 (3) | K1–O4iii | 3.407 (3) |
| K1–O2ii | 2.949 (3) | ||
| O1–K1–N1 | 147.60 (9) | O2ii–K1–O1ii | 72.20 (8) |
| O1–K1–N2 | 88.94 (8) | O1–K1–O3ii | 131.80 (8) |
| N1–K1–N2 | 59.17 (7) | N1–K1–O3ii | 80.01 (7) |
| O1–K1–O4i | 77.19 (9) | N2–K1–O3ii | 139.15 (7) |
| N1–K1–O4i | 106.36 (8) | O4i–K1–O3ii | 100.37 (7) |
| N2–K1–O4i | 90.52 (8) | O2ii–K1–O3ii | 41.60 (6) |
| O1–K1–O2ii | 103.78 (8) | O1ii–K1–O3ii | 51.33 (7) |
| N1–K1–O2ii | 98.26 (7) | O1–K1–O4iii | 54.53 (8) |
| N2–K1–O2ii | 139.51 (8) | N1–K1–O4iii | 148.89 (7) |
| O4i–K1–O2ii | 129.57 (9) | N2–K1–O4iii | 137.50 (7) |
| O1–K1–O1ii | 92.37 (9) | O4i–K1–O4iii | 100.10 (7) |
| N1–K1–O1ii | 117.06 (8) | O2ii–K1–O4iii | 51.41 (6) |
| N2–K1–O1ii | 146.60 (8) | O1ii–K1–O4iii | 64.97 (8) |
| O4i–K1–O1ii | 57.46 (9) | O3ii–K1–O4iii | 79.40 (7) |
Symmetry codes: (i) −x + 2, −y + 1, −z + 1; (ii) −x + 1, −y + 1, −z + 1; (iii) x – 1, y, z; (iv) x + 1, y, z.
Figure 4Molecular structure of [Li(phen)(H2O)2][dcf] (3); thermal ellipsoid are drawn at the 50% probability level.
Selected Geometric Parameters (Å, deg) for 3
| N1–Li1 | 2.108 (6) | Li1–O1 | 1.936 (6) |
| Li1–O2 | 1.921 (6) | Li1–N2 | 2.044 (6) |
| C12–N1–Li1 | 110.4 (3) | O2–Li1–N1 | 130.6 (3) |
| O2–Li1–O1 | 103.2 (3) | O1–Li1–N1 | 112.2 (3) |
| O2–Li1–N2 | 107.0 (3) | N2–Li1–N1 | 81.2 (2) |
| O1–Li1–N2 | 123.3 (3) |
Percent Inhibitory Concentration of Compounds on Different Cancer and Normal Cell Lines
| compounds | CAL-27 IC50 ± S.D | NCI-H460 IC50 ± S.D | NIH-3T3 IC50 ± S.D |
|---|---|---|---|
| 219.54 ± 0.93 | 211.02 ± 2.48 | >250 | |
| 1.69 ± 0.026 | 3.87 ± 0.04 | 54.83 ± 2.36 | |
| 2.95 ± 0.37 | 4.74 ± 0.86 | 53.49 ± 2.43 | |
| 3.19 ± 1.54 | 3.52 ± 0.004 | 135.21 ± 4.96 | |
| 5-fluorouracil | 2.41 ± 0.89 | 4.54 ± 1.67 | >100 μM |
Percent Biofilm Inhibitory Concentration against Pathogenic Microbes
| microorganisms | ||||||||
|---|---|---|---|---|---|---|---|---|
| MBIC | MBIC | MBIC | | |||||
| compounds | dose (μM) | % inhibition ± S.D | dose (μM) | % Inhibition ± S.D | dose (μM) | % Inhibition ± S.D | dose (μM) | % Inhibition ± S.D |
| 250 | 78.03 ± 0.062 | 250 | 76.83 ± 0.009 | 250 | 69.782 ± 0.065 | 500 | 0.374 ± 0.304 | |
| 250 | 77.26 ± 0.063 | 250 | 72 ± 0.091 | 250 | 86.158 ± 0.068 | 500 | –1.497 ± 0.288 | |
| 250 | 77.91 ± 0.062 | 250 | 76.22 ± 0.026 | 125 | 87.924 ± 0.073 | 500 | 3.306 ± 0.166 | |
| ND | ||||||||
Crystallographic Structural Data for Complexes 1–3
| 1 | 2 | 3 | |
|---|---|---|---|
| chemical formula | C52H44Cl4N6Na2O8 | C52H44Cl4K2N6O8 | C26H22Cl2LiN3O4 |
| MW | 1068.71 | 1100.93 | 518.30 |
| crystal system, space group | triclinic, P-1 | triclinic, P-1 | triclinic, P-1 |
| temperature (K) | 296 | 296 | 296 |
| 7.7547 (16), 10.787 (3), 15.807 (4) | 7.7271 (15), 11.280 (3), 15.239 (3) | 7.8276 (5), 10.9241 (8), 15.0459 (12) | |
| α, β, γ (deg) | 99.936 (10), 100.078 (9), 103.314 (9) | 95.707 (11), 100.032 (10), 100.209 (10) | 102.434 (4), 95.580 (3), 99.362 (3) |
| 1235.1 (5) | 1275.6 (5) | 1227.92 (16) | |
| Z | 1 | 2 | 2 |
| μ (mm–1) | 0.32 | 0.46 | 0.30 |
| 0.678, 0.745 | 0.681, 0.745 | 0.639, 0.745 | |
| no. of measured, independent and observed [ | 37 250, 5043, 3922 | 36 149, 5170, 3786 | 35 428, 5003, 3631 |
| 0.040 | 0.044 | 0.056 | |
| (sin θ/λ)max (Å–1) | 0.625 | 0.625 | 0.625 |
| 0.047, 0.121, 1.06 | 0.051, 0.158, 1.04 | 0.061, 0.151, 1.06 | |
| no. of reflections | 5043 | 5170 | 5003 |
| no. of parameters | 337 | 341 | 338 |
| no. of restraints | 3 | 5 | 4 |
| Δρmax, Δρmin (e Å–3) | +0.53, −0.55 | +0.55, −0.40 | +0.37, −0.51 |
| CCDC | 1 945 208 | 1 945 209 | 1 945 210 |